SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech - Technical Analysis
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jibacoa who wrote (46)4/19/2001 11:10:56 PM
From: Jibacoa  Read Replies (2) of 544
 
The following is an answer to a question from Scott about VICL on the Biotech Valuation thread:

As you said VICL is going to be under pressure tomorrow after the news today of discontinuing the present Phase II trial with Leuvecting in patients with metastatic renal neoplasms.

But Leuvecting is not their primary drug. Their lead immunotherapy product candidate is Allovectin-7 which is on Phase III for patients with malignant melanoma and on Phase II on patients with cancer of the head and neck. Also the base of their research is their patented "naked DNA gene transfer" using plasmids and without the need of a viral vector.

Both Leuvectin and Allovectin-7 are DNA/Lipid complexes, but Allovectin-7 contains the human gene encoding HLA-B7 antigen and Leuvectin contains the gene encoding IL-2

As far as your question of the support levels on the chart,
the nearest support is now at 15.05 (the intra-day H of 4/17)then as you mentioned the 14 level,(which was the intra-day Hs on 4/12 and 4/16)

VICL is still on a near-term up-trend that started on April 3 and was confirmed on April 5.

The present up-trend will not be broken as long as it remains above the April 5 H of 12.25 but if it it gets down to that level it will need some base bulding before resuming the uptrend.<g>

Again, I don't know if that will help you.<g>

siliconinvestor.com

Bernard
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News